ClinicalTrials.gg
CompletedNCT00724334Updated Oct 6, 2026Results posted

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

A Phase 1/2 interventional study of SAR302503 (TG101348) in Myelofibrosis, sponsored by Bristol-Myers Squibb. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 6, 2026Results postedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 1 of them phase 3. Primary Myelofibrosis · Bristol-Myers Squibb.

Enrollment
7th of 10
43 · median 92
Started
2008
the only one that year
Phase 1/2
3 of 14
none open now
Registered
2nd of 14
by date

Among the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 1/2, and was the 2nd registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

1 of the 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Primary Myelofibrosis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.

Read the detailed description

SAR302503 (TG101348) is a potent small molecule inhibitor of Janus kinase 2 (JAK2). This is an extension study for a first-in-man, dose escalation study (MF-TG101348-001). The safety, tolerability and clinical activity of SAR302503 (TG101348) in subjects with myelofibrosis will be evaluated.

03

Conditions studied

  • Myelofibrosis

Browse trials for

Keywords

  • myelofibrosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of MF-TG101348-001 study
  • Diagnosis of myelofibrosis
  • At least 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Any acute or chronic medical abnormality that may increase the risk associated with study participation
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    1

    Drug: SAR302503 (TG101348)

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Response (IWG-MRT) - Best Overall Response

    Best response categories per IWG-MRT response criteria across studies TED12037 and TED12015 combined. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission; SD indicates no meaningful change; and PD indicates disease worsening.

    Time frame: From enrollment to date of first objective response, or death due to any cause (up to approximately 52 months)

Secondary outcomes

  1. Time to Any Response

    Time to any first response (CR/PR/CI); median and range. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission.

    Time frame: From enrollment to date of first objective response, or death due to any cause (up to approximately 56 months)

  2. Duration of Response

    Duration of response (days); range. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission.

    Time frame: From enrollmen to death due to any cause (up to approximately 52 months)

  3. Spleen Size at Baseline (TED12037)

    Palpable spleen size in cm below the left costal margin at baseline of TED12037.

    Time frame: Baseline

  4. Transfusion Dependence at Baseline (TED12037)

    Transfusion dependence defined as RBC transfusion within 56 days before baseline of TED12037.

    Time frame: Baseline

07

Results

Posted Oct 6, 2026

Participant flow

Of the 59 patients enrolled in TED12037, 43 patients continued treatment in TED12015.

Participant flow — Overall Study
MilestoneSAR302503
Started43
Completed12
Not completed31

Outcome measures

PrimaryClinical Response (IWG-MRT) - Best Overall Response

Best response categories per IWG-MRT response criteria across studies TED12037 and TED12015 combined. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission; SD indicates no meaningful change; and PD indicates disease worsening.

Time frame:
From enrollment to date of first objective response, or death due to any cause (up to approximately 52 months)
Reported as:
Count of participants · Participants
Clinical Response (IWG-MRT) - Best Overall Response
ParticipantsSAR302503
Complete Remission (CR)1
Partial Remission (PR)0
Clinical Improvement (CI)31
Stable Disease11
Progressive Disease0
SecondaryTime to Any Response

Time to any first response (CR/PR/CI); median and range. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission.

Time frame:
From enrollment to date of first objective response, or death due to any cause (up to approximately 56 months)
Reported as:
Median · days
Time to Any Response
daysSAR302503
Time to Any Response140 ± 77
SecondaryDuration of Response

Duration of response (days); range. Responses were assessed using IWG-MRT criteria and categorized as complete remission (CR), partial remission (PR), clinical improvement (CI), stable disease (SD), or progressive disease (PD). CR and PR reflect disease modification with resolution or partial resolution of disease features; CI reflects improvement in key clinical parameters without full remission.

Time frame:
From enrollmen to death due to any cause (up to approximately 52 months)
Reported as:
Median · days
Duration of Response
daysSAR302503
Duration of ResponseNA (13 to 1537)
SecondarySpleen Size at Baseline (TED12037)

Palpable spleen size in cm below the left costal margin at baseline of TED12037.

Time frame:
Baseline
Reported as:
Mean · cm
Spleen Size at Baseline (TED12037)
cmSAR302503
Spleen Size at Baseline (TED12037)18.7 ± 6.40
SecondaryTransfusion Dependence at Baseline (TED12037)

Transfusion dependence defined as RBC transfusion within 56 days before baseline of TED12037.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Transfusion Dependence at Baseline (TED12037)
ParticipantsSAR302503
No28
Yes14

Adverse events

Collected over AEs/SAEs are collected from the first dose date until the last dose date + 30 days (up to approximately 55 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SAR3025038/43 (18.6%)23/43 (53.5%)43/43 (100%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventSAR302503
ThrombocytopeniaBlood and lymphatic system disorders3/43
PneumoniaInfections and infestations3/43
NeutropeniaBlood and lymphatic system disorders2/43
DiarrheaGastrointestinal disorders2/43
NauseaGastrointestinal disorders2/43
VomitingGastrointestinal disorders2/43
PyrexiaGeneral disorders2/43
Clostridium difficile colitisInfections and infestations2/43
Subdural hematomaInjury, poisoning and procedural complications2/43
DehydrationMetabolism and nutrition disorders2/43
Most frequent other events
Showing 10 of 121
Most frequent other events
EventSAR302503
(N=3) All Doses (N=43) InvestigationsInjury, poisoning and procedural complications41/43
DiarrhoeaGastrointestinal disorders35/43
NauseaGastrointestinal disorders35/43
AnaemiaBlood and lymphatic system disorders34/43
VomitingGastrointestinal disorders32/43
ThrombocytopeniaBlood and lymphatic system disorders30/43
Blood creatinine increasedInjury, poisoning and procedural complications24/43
Aspartate aminotransferase increasedInjury, poisoning and procedural complications20/43
FatigueGeneral disorders and administration site conditions19/43
Oedema peripheralGeneral disorders and administration site conditions19/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)SAR302503
Mean63.8 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)SAR302503
Female17
Male26
08

Study locations

6 sites
  • Investigational Site Number 840103
    La Jolla, California 92093, United States
  • Investigational Site Number 840102
    Stanford, California 94305, United States
  • Investigational Site Number 840105
    Boston, Massachusetts 02115, United States
  • Investigational Site Number 840106
    Ann Arbor, Michigan 48109-0759, United States
  • Investigational Site Number 840104
    Rochester, Minnesota 55905, United States
  • Investigational Site Number 840101
    Houston, Texas 77030, United States
09

References and documents

Related links

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2008 to primary completion in May 2014, 69 months.

Results were first posted in Oct 2026, 12 years 4 months after primary completion. A results delay was requested in Feb 2016.

Of 27 phase 1/2 interventional studies under Primary Myelofibrosis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 125. This study's 69 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2008
First posted
Jul 29, 2008
StartActual
Jul 31, 2008
Primary completionActual
May 28, 2014
CompletionActual
May 28, 2014
Results delay requested
Feb 17, 2016
Results first posted
Oct 6, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 6, 2026
Enrollment
42→43
Oct 6, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Safety (i.e. adverse events, effects on laboratory parameters, vital signs and ECGs) and tolerabilityNow Clinical Response (IWG-MRT) - Best Overall ResponseTime frame: 6 months → From enrollment to date of first objective response, or death due to any cause (up to approximately 52 months)
Oct 6, 2026
Secondary outcomes
4 added, 1 removed
What changed in the outcomes
  • AddedTime to Any ResponseTime frame: From enrollment to date of first objective response, or death due to any cause (up to approximately 56 months)
  • AddedDuration of ResponseTime frame: From enrollmen to death due to any cause (up to approximately 52 months)
  • AddedSpleen Size at Baseline (TED12037)Time frame: Baseline
  • AddedTransfusion Dependence at Baseline (TED12037)Time frame: Baseline
  • RemovedClinical activity and pharmacodynamicsTime frame: 6 months
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Results posted
    Enrollment 42→43
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Safety (i.e. adverse events, effects on laboratory parameters, vital signs and ECGs) and tolerabilityNow Clinical Response (IWG-MRT) - Best Overall ResponseTime frame: 6 months → From enrollment to date of first objective response, or death due to any cause (up to approximately 52 months)
    Secondary outcomes 4 added, 1 removed
    What changed in the outcomes
    • AddedTime to Any ResponseTime frame: From enrollment to date of first objective response, or death due to any cause (up to approximately 56 months)
    • AddedDuration of ResponseTime frame: From enrollmen to death due to any cause (up to approximately 52 months)
    • AddedSpleen Size at Baseline (TED12037)Time frame: Baseline
    • AddedTransfusion Dependence at Baseline (TED12037)Time frame: Baseline
    • RemovedClinical activity and pharmacodynamicsTime frame: 6 months
    + 3 other changes: verification date, date precision and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT00724334
Responsible party
Sponsor
First posted
Jul 29, 2008
Start date
Jul 31, 2008
Primary completion
May 28, 2014
Completion
May 28, 2014
Results posted
Oct 6, 2026
Last update
Oct 6, 2026

Study contacts

Ayalew Tefferi, MD
study chair · Mayo Clinic, Rochester, MN

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fedratinib

Start the discussion